Corient IA LLC Makes New Investment in DiaMedica Therapeutics, Inc. $DMAC

Corient IA LLC acquired a new stake in shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) in the third quarter, HoldingsChannel reports. The firm acquired 132,500 shares of the company’s stock, valued at approximately $910,000.

Other large investors have also recently made changes to their positions in the company. Police & Firemen s Retirement System of New Jersey bought a new position in DiaMedica Therapeutics during the second quarter valued at approximately $29,000. Bank of America Corp DE increased its stake in DiaMedica Therapeutics by 3,710.3% in the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after acquiring an additional 8,274 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of DiaMedica Therapeutics during the 2nd quarter worth approximately $49,000. Invesco Ltd. purchased a new stake in shares of DiaMedica Therapeutics during the 2nd quarter worth approximately $54,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of DiaMedica Therapeutics during the 2nd quarter valued at approximately $56,000. 10.12% of the stock is owned by institutional investors.

DiaMedica Therapeutics Trading Up 0.8%

Shares of DMAC opened at $7.77 on Thursday. DiaMedica Therapeutics, Inc. has a twelve month low of $3.19 and a twelve month high of $10.42. The company’s fifty day simple moving average is $8.24 and its 200-day simple moving average is $7.50. The company has a market cap of $404.66 million, a P/E ratio of -10.94 and a beta of 1.09.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on DMAC shares. Cantor Fitzgerald initiated coverage on shares of DiaMedica Therapeutics in a research report on Friday, November 14th. They issued an “overweight” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, January 21st. Lake Street Capital restated a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Finally, Wall Street Zen cut shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

DiaMedica Therapeutics Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.